Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway by Xing Luo, Yi Duan, Jinwei He, CongGai Huang, Jun Liu, Yifan Liu, Mengdei Xu, Qiong Dai, Zhihui Yang

“…Finally, we proved that the combined therapy of DHT and BRAF/MEK inhibitors is reliable and effective at animal and cell levels.ConclusionIn BRAF mutant melanoma cells, DHT suppresses the STAT3/SOX2 signaling pathway. …”
Get full text

Anemia, Thrombocytopenia, and Changes in Biochemical Parameters Occurring in Patients with Uncomplicated Plasmodium falciparum Malaria: Data Analysis from Antimalarial Efficacy-Ran... by Khadime Sylla, Roger Tine, Doudou Sow, Souleye Lelo, Annie Abiola, Jean Louis NDiaye, Magatte NDiaye, Kuaku Folly, Léon Amath NDiaye, Oumar Gaye, Babacar Faye

“…Artemisinin-based Combination Therapies (ACTs) are widely used in the treatment of uncomplicated malaria. …”
Get full text

Sodium Butyrate: A Multifaceted Modulator in Colorectal Cancer Therapy by Alexandra Laura Mederle, Alexandra Semenescu, George Andrei Drăghici, Cristina Adriana Dehelean, Nicolae-Valentin Vlăduț, Dragoş Vasile Nica

“…These findings support its potential for integration into combination therapies or dietary interventions aimed at enhancing colonic butyrate levels.…”
Get full text

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer by Charlotte K. Kindt, Sidse Ehmsen, Sidse Ehmsen, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Henrik J. Ditzel, Henrik J. Ditzel, Carla L. Alves

“…High expression of the receptor tyrosine kinase REarranged during Transfection (RET) has been associated with resistance to endocrine therapy in breast cancer, but the role of RET in CDK4/6i treatment response/resistance remains unexplored.MethodsTo identify gene expression alterations associated with resistance to combined endocrine therapy and CDK4/6i, we performed RNA sequencing of two ER+ breast cancer cell models resistant to this combined therapy. The functional role of RET was assessed by siRNA-mediated RET silencing and targeted inhibition with the FDA/EMA-approved RET-selective inhibitor selpercatinib in resistant breast cancer cells and patient-derived organoids (PDOs). …”
Get full text

Effects of Jianpi therapy for cancer-related fatigue:a meta-analysis of randomized controlled trials by Jiaxing Dai, Jiaxing Dai, Huili Shui, Huili Shui, Huili Shui, Yuan Wu, Huanghui Zhang, Huanghui Zhang, Yuanyin Li, Yuanyin Li, Shaowang Zhang, Shaowang Zhang, Bing Yang, Bing Yang, Bing Yang, Dongxin Tang, Dongxin Tang, Dongxin Tang

“…The meta-analysis indicated that Jianpi decoction alone exhibited the most significant improvement in the proportion of CD4 cells (SMD=1.34, 95% CI 0.54 to 2.31, P<0.001) and hemoglobin (MD=7.45, 95% CI 4.18 to 10.72, Z=4.47, P<0.001), while also more significantly reducing Piper Fatigue Scale scores (SMD=-2.05, 95% CI -2.71 to -1.39, P<0.001). The combined therapy, which integrated Jianpi therapy with standard care, demonstrated the greatest advantage in enhancing the proportion of CD3 cells (SMD=1.25, 95% CI 0.46 to 2.04, P<0.001). …”
Get full text

Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data by Zhihao Li, Daniel Aliseda, Owen Jones, Luckshi Rajendran, Christian Magyar, Robert Grant, Grainne M. O’Kane, Anna Saborowski, Gonzalo Sapisochin, Arndt Vogel

“…Further improvements in treatment efficacy may require biomarker identification to optimize combinational therapies for better patient selection. Impact and implications: This study analyzed recent RCTs, including KEYNOTE-966, TOPAZ-1, NIFE, and SWOG 1815, involving 4,584 patients with advanced biliary tract cancer. …”
Get full text